Article Text

Download PDFPDF

537 FERTility sparing treatment in patients with ENdometrial Cancer (FERT-ENC) from the Spanish Investigational Network Gynecologic Oncology Group
  1. V Lago1,
  2. MT Marina Martín1,
  3. M Laseca Modrego2,
  4. B Gil Ibanez3,
  5. JR Rodriguez4,
  6. J Domingo5,
  7. L Minig6,
  8. P Padilla Iserte1,
  9. O Arencibia Sanchez2,
  10. M Sala Ferichola7,
  11. M Munmany8,
  12. B Martin9,
  13. S Iacoponi10;11,
  14. S Cabrera12,
  15. P Coronado13,
  16. J Utrilla Layna14,
  17. A Bataller Calatayud15,
  18. G Fiol16,
  19. S Corbalán17 and
  20. S Domingo1
  1. 1University Hospital La Fe, Spain
  2. 2Maternal and Child University Hospital of the Canarias
  3. 3University Hospital 12 de Octubre
  4. 4Clinic and University Hospital Virgen de la Arrixaca
  5. 5IVI Las Palmas
  6. 6CEU Cardenal Herrera University
  7. 7General University hospital of Alicante
  8. 8Clinic University Hospital
  9. 9University Hospital Getafe
  10. 10Hospital Quironsalud Madrid
  11. 11University Hospital Quironsalud Madrid, Gynecology , Pozuelo de Alarcón, Spain
  12. 12University hospital Vall d´hebron
  13. 13Clinic University Hospital San Carlos
  14. 14University Hospital Fundación Jimenez Díaz
  15. 15University Hospital of La Rivera
  16. 16University Hospital Torrecárdenas
  17. 17University Hospital Los Arcos


Introduction/Background*The primary objective was to evaluate the response rate of conservative treatment in endometrial cancer and the secondary objective was to assess oncological, fertility and obstetric outcomes in fertility preservation patients

Methodology This was a multi-centre, observational, retrospective study of endometrial cancer patients who underwent fertility-sparing treatment in Spanish centres (January 2010–2020). Seventy-three patients with stage IA, endometrioid adenocarcinoma of the uterus were included in the study.

Result(s)*The levonorgestrel intrauterine device (LNG-IUD) was the most used method (53.4%), followed by megestrol acetate (20.5%) and medroxyprogesterone acetate (16.4%). During the 24-month follow-up, the rate of complete response to the fertility-sparing management was 74% (n = 54/73) and 8.2% (n = 6/73) patients presented a partial response. Additionally, 13 (17.8%) patients presented with persistent disease and six (8.2%) patients relapsed after response. The use of LNG-IUD was associated with a higher complete response rate (LNG-IUD 87.2% vs. others 58.8%; p = 0.01). Surgical treatment (at least hysterectomy) was completed in 44 (60.3%) patients. Four (5.5%) patients presented with relapse after surgery being associated with it the final stage FIGO III (p = 0.036), myometrial invasion > 50% (p = 0.018), and final tumour grade 2–3 (p = 0.018). The mean follow-up was 57.8 (range 6–159) months. The five-year relapse-free survival and overall survival were 92.6% (95% CI: 81.3–97.2%) and 93.5% (95% CI: 80.7–97.9%), respectively. The rate of pregnancy was 81.1% (n = 30/37), using, in most cases, reproductive techniques (78.4%) for this purpose.

Conclusion*Fertility-sparing management presents a high response rate in endometrial cancer . The use of LNG-IUD associates a better response rate, when compared to other treatment options. Moreover, pregnancy can be achieved with this management by use of reproductive techniques.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.